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the amount of trapped cells and their viability. There were no acute complications (death, 
tamponada, ventricular perforation, arrhythmia). Preliminary in vitro testing of cell viability 
after passage through the catheter yielded a 86.6 +/- 2.5% (mean +/- SEM) rate which 
was highly pressure-dependent. Following explantation, clusters of SM could be hlstolog- 
ically identified by computerized assisted analysis in the anterior, apical and septal walls 
in the 6 hearts and represented 11 +/- 2.2% of the initial injectate. The viability of grafted 
SM retrieved from the transplanted area and assessed by a positive staining for CD 56 
averaged 3%. This percentage which might represent an underestimation due to injec- 
tion in non infracted myocardium, is still 10 fold higher than that previously observed after 
SM injections through an endovascular catheter. These preliminary data suggest that the 
CS route could represent a safe and effective mean of percutaneous SM intramyocardial 
transfer but improvements in delivery systems remain mandatory to reduce physical train 
during injections and consequently optimise cell survival. 
1176-197 Combination of a Direct Thrombin Inhibitor, Argatroban, 
and Glycoprotein Ilb/llla Inhibitor Is Effective and Safe 
in Patients Undergoing Percutaneous Coronary 
Intervention 
Ik-Kvuna Jan& Bruce E. Lewis, William H. Matthai. Neal S. Kleiman, Massachusetts 
General Hospital, Boston, MA, Baylor College of Medicine, Houston, TX 
Background: Argatroban, a small molecule direct thrombin inhibitor, has been shown to 
block clot bound thrombin more effectively than does unfractionated heparin. Argatroban 
has not been systematically tested in patients undergoing percutaneous coronary inter- 
vention (PCI) with concurrent glycoprotein (GP) Ilb/llla. 
Methods: In this multicenter. prospective, pilot study argatroban was administered in 
patients undergoing PCI at 250 mcglkg bolus followed by 15 mcglkglmin during the pro- 
cedure. Additional boluses of 150 mcgikg were given, if ACT did not reach the target 
range of 275-325 sec. GP Ilb/llla inhibitor was administered simultaneously. The primary 
efficacy endpoint was vascular death, myocardial infarction (Ml), or urgent revasculariza- 
tion at 30 days. The safety endpoint was in-hospital major bleeding. MI was defined as 
CKMB elevation more than 3 times the upper limit of normal or cardiac symptoms with 
supportive cardiac marker or EKG evidence. 
Results: A total of 101 patients were enrolled and completed the PCI procedure. There 
were 72 males and the mean age was 65 years. Abciximab was given to 99 patients and 
double bolus eptifibatide to 2 patients. 76 patients had one target lesion treated and the 
rest, two or more lesions. 96 patients were treated with stenting. Second and third 
boluses of argatroban were required in 22 and 7 patients, respectively. The target ACT 
was achieved in 94 patients. The primary efficacy endpoint occurred in 3 (3.0%) patients 
(no vascular death, 3 MIS and 2 urgent revascularizations). Two additlonal patients had 
cardtac symptoms and elevated troponin without significant CKMB elevation. There were 
2 major bleeding events (1 retroperitoneal, 1 groin hematoma). Conclusion:Argatroban 
!n combination with GP Ilb/llla inhibitors provides adequate anticoagulation with accept- 
able bleeding risk. These data suggest that further investigation of argatroban in patients 
undergoing PCI is warranted. 
1176-196 Unfractionated Heparin Increases Platelet-Monocyte 
Binding In Vitro and in Patients Undergoing 
Percutaneous Coronary Intervention 
Scott Hardinq, Debra H. Josephs. David E. Newby, Ian Dransfield, Chris Haslett, Keith A. 
A. Fox. Jaydeep Sarma, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom 
Background: Unfractionated heparin is currently considered to be the anticoagulant of 
choice in patients undergoing percutaneous coronary intervention (PCI). Unfractionated 
heparin may be associated with adverse platelet actwation. Platelet-monocyte aggrega- 
tion (PMA) is a sensitive marker of platelet activation and may mediate pro-inflammatory 
cytokine release, tissue factor expression and augmented adhesion molecule expres- 
sion. We compared the effects of unfractionated heparin, a low-molecular-weight-heparin 
(enoxaparin). and a direct thrombin inhibitor (lepirudin) on PMA in vitro. We also investi- 
gated the effects of unfractionated heparin on PMA in patients prior to PCI. 
Methods: Peripheral venous blood was collected from 16 healthy volunteers into sodium 
citrate alone or sodium citrate with unfractionated heparin (1 U/ml), enoxaparin (0.6 U/ml) 
or lepirudin (56~g/ml). Blood was also drawn into sodium citrate tubes from 14 patients 
immediately before and five minutes after administration of 100 U/kg of unfractionated 
hepann, prior to elective PCI. PMA was determined by 2.color flow-cytometric analysis. 
Results: In healthy volunteers, PMA was higher in blood anticoagulated with sodium cit- 
rate and unfractionated heparin (20.1 * 1.9%) compared to sodium citrate alone (16.2 + 
1.6%, pcO.001) or sodium citrate with enoxaparin (16.9 * 2.0%, pcO.01) or lepirudin 
(17.0 + 2.2%, p<O.Ol). There were no differences in PMA in blood anticoagulated with 
sodium citrate alone, sodium citrate and enoxaparm, or sodium citrate and lepirudin 
(p=ns). Administration of unfractlonatsd heparin to patients prior to PCI was also associ- 
ated with increased PMA (24.2 f 2.6% vs. 16.9 * 2.4%, p<O.Ol). 
Conclusions: In contrast to enoxaparin and kpirudin, unfractionated heparin increases 
PMA in vitro: an effect that was also demonstrable in patients receiving unfractionated 
heparin prior to PCI. Given that PMA is a sensitive measure of platelet activation and 
may have proinflammatory consequences, the use of alternative anticoagulant regimens 
may reduce PCI associated complications. 
1176-199 Safety and Efficacy of Subcutaneous Enoxaparin in 
Early Invasive Strategy of Unstable Angina 
Jean-Philippe Collet, Gilles Montalescot, Jean-Louis Golmard, M. Tanguy, Remi 
Choussat, Gerard Drobinski, Annick Ankri. Nicolas Vignolles, Daniel Thomas, Pitie 
SalpBtriBre, Paris, France 
Introduction : We have demonstrated previously that subcutaneous (s/c) enoxaparin 
(1 mglKg/lPh) given during at least 46 hours provided good anticoagulation and clinical 
results in non-ST elevation acute coronary syndromes (NSTE-ACS) patients undergoing 
percutaneous coronary intervention (PCI) within 6 hours of the last injection. We evalu- 
ated whether an early invasive (El) strategy with only 2 injections of sic enoxaparin was 
as good as a delayed invasive (DI) strategy with 3 injections or more. 
Methods and results : We compared NSTE-ACS patients who underwent PCI after 2 
injections of s/c enoxaparin (El. n=ll7) with those referred later on (DI, 5.9AO.2 s/c injec- 
tions. n=230). Anti-Xa at the time of catheterization, safety and major coronary events 
(death/Ml) were assessed at 30 days. Baseline characteristics were similar in the 2 
groups of patients. The period of medical stabilization was 20.5+1.0 hrs in the ‘“El” and 
69.2i3.0 hrs in the “DI” group, respectively (p<O.OOOl). The anti-Xa activity measured at 
the time of catheterization (0.92+0.04 U/mL vs 0.96+0.02 U/mL. p=O.25) and the injection 
to catheterization time (5.6kO.2 hrs. vs 5.2iO.l hrs, p=O.17) were similar in both groups. 
Patients of the “El” group were more frequently treated by Ilb/llla inhibitors and clopi- 
dogrel before PCI than patients of the “DI” group (56.1% vs 31.7%. pcO.0001 for GPllbl 
llla inhibitors and 66.4% vs 40.4% for clopidogrel pretreatment, p<O.OOOi, respectively). 
Bleeding rates were found to be equivalent between both groups (1.7% vs 4.6%, for “El” 
and “DI” strategies respectively, p=O.23, one-sided 95% Cl of 0.626). There was a non 
significant trend for less death or Ml at 30 days in the ‘“El” group compared to the “DI” 
group (4.3% vs 7.0%, respectively, p=O.32, one-sided 95% Cl of 1.536). 
Conclusion: In patients with NSTE-ACS, a rapid invasive strategy with only 2 s/c injec- 
tions of enoxaparin provides similar levels of anticoagulation and similar bleeding rates 
with a trend for less ischemic major events as a more prolonged “upstream” treatment 
with enoxaparin. 
1176-200 Assessment of Anticoagulation Using Activated 
Clotting Times in Patients Receiving Intravenous 
Enoxaparin During Percutaneous Coronary Intervention 
Mark Lawrence, Timothy Mixon, Donald Cross, Gregory Dehmer, Scott and White Clinic, 
Temple, TX 
Background: Low molecular weight heparins have many advantages over unfraction- 
ated heparin. They have been used safely during percutaneous coronary intervention 
(PCI) when given intravenously (IV) with and without glycoprotein 2bl3a receptor inhibi- 
tors. lnterventionalists have been reluctant to use this therapy because of the inability to 
monitor the anticoagulant effect of IV enoxaparin. We measured activated clotting time 
(ACT), before and after IV enoxaparin, to determine if anticoagulation could be assessed 
with this standard test. 
Methods: 45 consecutive patients undergoing PCI received either 0.75 mg!kg IV enox- 
aparin if they also received eptifibatide, or 1 mglkg IV enoxaparin if no eptifibatide was 
given. ACT was measured using the Hemochron device before and 5 minutes following 
IV enoxaparin administration. 
Resuks: After 0.75 mg/kg enoxaparin, mean ACT Increased from 132 _c 31 set to 207+ 
25 sec. (pcO.001). After 1 mg/kg enoxaparin. ACT increased from 121 -+ 26 set to 212+ 
32 ssc, (p<O.OOl). The mean increase in ACT value was 74 f 20 set (range 47 to 132) in 
the 0.75 mglkg group (n=36) and 92 + 26 set (range 32 to 120) in the 1 mg/kg group 
(n=9). None of the patients had transient abrupt closure, thrombus formation, major 
bleeding or required urgent revascularization. 
Conclusions: Intravenous enoxaparin at clinically relevant doses, increases ACT levels 
in patients undergoing PCI with and without eptifibatide. These data suggest that ACT 
may be useful in the measurement of enoxaparin anticoagulation. 
1176-201 A Randomized Comparison of Dalteparin Versus 
Unfractionated Heparin During Percutaneous Coronary 
Interventions 
Madhu K. Nataraian. Graham A. Turpie, Dominic L. Race. James L. Velianou, Shamlr R. 
Mehta, Rizwan Afzal. David R. Goodhart, Jeffrey S. Ginsberg, McMaster University, 
Hamilton, ON, Canada 
Background: Low molecular weight heparins are widely used in patients with coronary 
artery disease but experience with them during percutaneous coronary interventions 
(PCI) is limited. The purpose of this study was to compare the safety and efficacy of the 
low molecular weight heparin, dalteparin (Dalt.) to unfractionated heparin (UFH). 
Methods: A single-centre, randomized, double-blind study of Dalt. versus UFH in patients 
undergoing PCI was camed out. All patients undergoing planned or ad-hoc PCI (exclud- 
ing emergency PCI post-thrombolysis or for shock) were eligible. Randomization was 
